middl
east
respiratori
syndrom
coronaviru
merscov
reach
republ
korea
result
nosocomi
transmiss
largest
epidem
outsid
arabian
peninsula
date
despit
variou
strategi
identifi
cov
intervent
limit
therapeut
option
avail
address
unmet
medic
need
use
south
korean
merscov
clinic
isol
screen
compound
includ
us
food
drug
administr
fda
approv
drug
bioactiv
molecul
confirm
hit
doserespons
curv
analysi
primari
assay
select
hit
therapeut
index
ti
greater
timeofaddit
studi
fdaapprov
drug
demonstr
eight
four
therapeut
act
earlyand
late
stage
viral
life
cycl
respect
among
earli
act
drug
three
therapeut
ti
greater
cardioton
agent
togeth
result
identifi
potenti
therapeut
option
treatment
merscov
infect
could
provid
basi
wider
rang
coronavirus
includ
current
emerg
coronaviru
diseas
outbreak
patient
late
stage
infect
omrani
et
al
shalhoub
et
al
spanaki
et
al
result
suggest
administr
broadspectrum
antivir
mer
patient
effect
point
infect
although
specif
treatment
merscov
may
requir
full
antivir
activ
current
sever
outbreak
coronaviru
diseas
emerg
wuhan
china
late
sever
countri
worldwid
battl
control
spread
devast
viru
ongo
outbreak
accompani
mani
human
casualti
signific
socioeconom
loss
global
reach
proport
pandem
confirm
case
relat
fatal
worldwid
februari
unfortun
covspecif
fdaapprov
drug
still
avail
clinic
studi
address
urgent
unmet
medic
need
facilit
develop
identif
appropri
effect
medic
care
patient
infect
cov
implement
highcont
screen
hc
strategi
goal
repurpos
newli
identifi
inhibitor
merscov
wider
rang
cov
includ
therapi
util
korean
merscov
patient
isol
screen
compound
contain
unit
state
food
drug
administr
fda
approv
drug
bioactiv
kinas
inhibitor
natur
product
librari
includ
fdaapprov
drug
total
fig
compound
test
antimerscov
activ
determin
level
viral
spike
protein
express
infect
vero
cell
immunofluoresc
analysi
ifa
screen
conduct
twotim
independ
screen
screen
use
chloroquin
refer
inhibitor
maximum
inhibitori
concentr
de
wild
et
al
calcul
zfactor
indic
good
separ
infect
cell
treat
dimethyl
sulfoxid
dmso
control
chloroquin
fig
two
independ
hc
analys
conduct
r
select
hit
demonstr
high
degre
correl
two
replic
fig
primari
hit
select
choos
demonstr
merscov
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
inhibit
cell
viabil
result
identif
compound
fig
hit
confirm
use
drc
analysi
assay
inhibitori
concentr
cytotox
concentr
determin
compound
fig
repres
exampl
drc
analysi
shown
supplementari
fig
base
analysi
regard
compound
therapeut
index
ti
ratio
valu
inact
elimin
confirm
hit
list
result
confirm
hit
select
final
hit
vitro
ti
test
fig
approach
aim
identifi
fdaapprov
drug
bioactiv
could
promptli
reposit
develop
respect
treat
merscov
potenti
patient
previous
report
studi
small
molecul
librari
includ
approxim
drug
fdaapprov
clinic
develop
screen
merscov
de
wild
et
al
dyall
et
al
screen
includ
fdaapprov
drug
cover
approxim
fdaapprov
compound
result
identifi
drug
found
previou
studi
indic
still
opportun
identifi
novel
fdaapprov
drug
bioactiv
screen
larger
compound
librari
moreov
corrobor
four
previous
identifi
hit
includ
emetin
dihydrochlorid
ouabain
cycloheximid
nelfinavir
mesyl
strongli
suggest
despit
use
differ
viral
isol
hc
assay
previous
publish
screen
reproduc
identifi
drug
could
repurpos
potenti
therapeut
option
patient
suffer
cov
infect
dyall
et
al
next
use
publicli
avail
drug
databas
classifi
entir
compound
librari
well
final
hit
compound
categori
distinct
pharmacolog
action
result
shown
fig
distribut
entir
librari
shown
gray
bar
final
hit
indic
black
import
note
cardiovascular
agent
group
contain
compound
ti
final
hit
analysi
found
major
final
hit
classifi
cardiovascular
agent
belong
class
cardiac
glycosid
cardiac
glycosid
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
natur
deriv
agent
use
treatment
cardiac
abnorm
function
modul
regul
sodiumpotassium
pump
prassa
diamandi
notabl
howev
glycosid
also
report
possess
antivir
activ
herp
simplex
viru
human
cytomegaloviru
bertol
et
al
kapoor
et
al
consist
previou
studi
data
indic
cardiac
glycosid
ouabain
digitoxin
digoxin
effici
inhibit
merscov
infect
ouabain
particular
found
block
entri
stage
coronavirus
merscov
src
kinas
signal
burkard
et
al
base
data
specul
cardiac
glycosid
may
gener
act
antimerscov
agent
blockag
viral
entri
howev
experiment
work
requir
elucid
exact
mechan
occur
fdaapprov
drug
inhibitor
known
biolog
function
particularli
advantag
repurpos
due
known
pharmacolog
activ
safeti
profil
potenti
facilit
faster
develop
drug
respect
therefor
priorit
fdaapprov
drug
six
bioactiv
yet
report
anticov
activ
summar
inform
tabl
tabl
investig
whether
fdaapprov
drug
act
earlyor
late
stage
preor
postentri
viral
life
cycl
inhibit
conduct
timeofaddit
studi
therefor
vero
cell
treat
drug
concentr
higher
valu
h
prior
h
postinfect
hpi
viral
infect
quantifi
ifa
previous
describ
infect
cell
treat
dmso
normal
infect
chloroquin
use
earli
stage
inhibitor
control
inhibit
merscov
infect
hpi
signific
effect
administ
hpi
fig
similar
effect
observ
treatment
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
biorxiv
preprint
ouabain
digitoxin
digoxin
niclosamid
regorafenib
nelfinavir
mesyl
ciclesonid
benidipin
hydrochlorid
inhibit
merscov
infect
administ
hpi
consist
previou
report
indic
ouabain
cardioton
steroid
effect
block
clathrinmedi
endocytosi
coronavirus
burkard
et
al
zumla
et
al
fig
supplementari
fig
contrast
atovaquon
lercanidipin
hydrochlorid
permethrin
octocrylen
minor
inhibitori
effect
throughout
timecours
assay
indic
drug
like
act
later
stage
viral
life
cycl
supplementari
fig
notabl
result
indic
lercanidipin
hydrochlorid
benidipin
hydrochlorid
dihydropyridin
calcium
channel
blocker
display
differ
pattern
viral
inhibit
epstein
yao
et
al
observ
could
explain
type
calcium
channel
drug
block
benidipin
hydrochlorid
block
tripl
voltageg
calcium
channel
inhibitor
wherea
lercanidipin
hydrochlorid
block
singl
voltageg
channel
klein
h
ozawa
et
al
wirtz
herzig
togeth
identifi
fdaapprov
drug
could
consid
reposit
merscov
therapi
especi
cardioton
drug
ouabain
digitoxin
digoxin
ti
greater
monotherapi
combin
remdesivir
drug
current
clinic
trial
treatment
therapeut
might
lead
drug
synerg
howev
vitro
vivo
studi
requir
investig
exact
antivir
mechan
determin
potenti
synergist
effect
confirm
antivir
efficaci
anim
model
priorit
select
drug
potenti
use
patient
affect
ongo
outbreak
seven
fdaapprov
drug
shown
fig
analyz
timeofaddit
assay
experi
describ
fig
authorfund
right
reserv
reus
allow
without
permiss
copyright
holder
preprint
peerreview
http
doi
supplementari
